drugset
drugset / Trial / NCT01666327

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of MT-1303 in Subjects With Inflammatory Bowel Disease

NCT01666327 ↗

Phase 1 Completed 18 enrolled Tanabe Pharma Corporation
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of a single oral dose of MT-1303 in subjects with inflammatory bowel disease.

Timeline

Start
2012-06
Primary completion
2014-07
Completion
2014-07

Drugs

EvaluationDrugModalityDoseRoute
Subject amiselimod Small molecule — Oral

Indications

inflammatory bowel disease